Related Experiment Video

Updated: May 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor

Yohann Loriot1, Amina Zoubeidi, Martin E Gleave

  • 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.

The Urologic Clinics of North America
|October 23, 2012
PubMed

Insights

Prostate cancer often progresses to castration-resistant prostate cancer (CRPC). This review explores novel therapeutic targets beyond androgen receptor signaling, including tubulin and DNA repair pathways, for CRPC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer is a leading cause of cancer-related death in men.
  • Androgen deprivation therapy is a common initial treatment for prostate cancer.
  • Castration-resistant prostate cancer (CRPC) eventually develops, driven by androgen receptor signaling and other pathways.

Purpose of the Study:

  • To review preclinical data and clinical trial status for novel therapeutic targets in CRPC.
  • To explore targets beyond the androgen receptor signaling pathway.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of current clinical trial data.
  • Focus on therapeutic targets including tubulin, DNA repair, molecular chaperones (CLU, Hsp27), and tyrosine kinases.

Main Results:

  • Androgen receptor signaling is a key driver in CRPC.
  • Emerging evidence indicates involvement of other pathways in CRPC progression.
  • Multiple novel therapeutic targets are under investigation in clinical trials.

Conclusions:

  • Targeting pathways beyond androgen receptor signaling holds promise for CRPC treatment.
  • Further research and clinical trials are necessary to validate these novel therapeutic strategies.
  • Developing new treatments for CRPC is crucial to improve patient outcomes.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...